Form 8-K - Current report:
SEC Accession No. 0001193125-25-024319
Filing Date
2025-02-11
Accepted
2025-02-11 16:13:02
Documents
15
Period of Report
2025-02-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d933485d8k.htm   iXBRL 8-K 25282
2 EX-99.1 d933485dex991.htm EX-99.1 68599
6 GRAPHIC g933485g90h59.jpg GRAPHIC 2752
  Complete submission text file 0001193125-25-024319.txt   229275

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sage-20250211.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20250211_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20250211_pre.xml EX-101.PRE 10810
18 EXTRACTED XBRL INSTANCE DOCUMENT d933485d8k_htm.xml XML 3555
Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 25609949
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)